文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌主动监测与放疗的Medicare总费用随时间变化

Changes Over Time in Total Medicare Costs for Active Surveillance Versus Radiation Therapy in Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-02-14

本研究基于SEER-Medicare数据,评估低危或有利中危前列腺癌男性中主动监测(AS)与放疗(RT)的总Medicare费用差异是否随时间变化。结果显示AS费用因监测和并发症管理而上升,RT费用在治疗、监测和并发症管理方面均下降,AS与RT的费用差距从2010-2014到2015-2019期间平均缩小3777美元,但AS仍是最低成本策略。

要点

  • AS费用随时间增加,主要由监测和并发症费用驱动。
  • RT费用在治疗、监测和并发症管理方面均下降。
  • AS与RT费用差距平均缩小3777美元,但AS仍最便宜。

核心结论

  • AS仍是最低成本策略,但AS与RT的总费用差距随时间缩小,可能与AS强化和RT降强化有关。

研究设计与样本

  • 基于SEER-Medicare数据,计算低危或有利中危前列腺癌患者诊断后3年内AS与4种RT模式(近距离放疗、立体定向体部放疗、调强放疗、质子束治疗)相关的治疗、监测和并发症管理费用,并调整至2017年美元。
  • 采用多变量模型评估2010-2014年与2015-2019年诊断患者中AS与RT费用差距是否变化。

主要发现

  • AS费用随时间增加,由监测和并发症费用驱动;RT费用在治疗、监测和并发症方面均下降。
  • 调整患者和临床因素后,AS与RT(所有模式合并)的费用差距从早期到后期平均缩小3777美元。
  • 各RT模式与AS的费用差距均随时间缩小:近距离放疗607美元、立体定向体部放疗4408美元、调强放疗5385美元、质子治疗3663美元,但近距离放疗的差异无统计学显著性。

关键数值与推荐

  • AS与RT(所有模式合并)费用差距平均缩小3777美元(从2010-2014到2015-2019诊断期间)。
  • 近距离放疗与AS费用差距缩小607美元(无统计学显著性)。
  • 立体定向体部放疗与AS费用差距缩小4408美元。
  • 调强放疗与AS费用差距缩小5385美元。
  • 质子治疗与AS费用差距缩小3663美元。

临床怎么用

  • 在低危或有利中危前列腺癌的决策中,可参考AS与RT费用差距随时间缩小的趋势,但AS仍为最低成本策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study evaluated whether the difference in total Medicare costs between active surveillance (AS) and radiation therapy (RT) changed over time for men with low- or favorable intermediate risk prostate cancer. METHODS AND MATERIALS: Using Surveillance, Epidemiology, and End Results-Medicare data, we calculated the costs associated with AS versus 4 RT modalities: brachytherapy, stereotactic body RT, intensity modulated RT, and proton beam therapy. We included costs that pertained to treatment, surveillance, and morbidity management for each patient, for 3 years after diagnosis. Costs were adjusted to 2017 dollars. Multivariable models assessed whether the cost gap between AS and RT changed between patients diagnosed in 2 time periods (2010-2014 vs 2015-2019). RESULTS: AS costs increased over time, driven by surveillance and morbidity expenses, whereas RT costs decreased across treatment, surveillance, and morbidity. After adjusting for patient and clinical factors, the cost gap between AS and RT (all modalities combined) decreased by a mean of $3777 from the earlier to the later period. A decrease in the cost gap over time between AS versus RT was observed for all RT modalities ($607 for brachytherapy, $4408 for stereotactic body RT, $5385 for intensity modulated RT, and $3663 for proton therapy), although it was not statistically significant for brachytherapy. CONCLUSIONS: Although AS remains the least costly approach, the cost gap between AS and RT has decreased over time, which may be related to the intensification of AS and the deintensification of RT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Shen J, Chen RC, Sayan M, et al. Changes Over Time in Total Medicare Costs for Active Surveillance Versus Radiation Therapy in Prostate Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 41698468. doi:10.1016/j.ijrobp.2026.02.204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。